Presbia Receives Registration Approval for Flexivue Microlens® in Israel
Treatment for Near Vision Loss Now Commercially Available in More Than 40 Countries Worldwide
AMSTERDAM--(BUSINESS WIRE)--Presbia, a medical device company and leader in near vision restoration, announced today that it has received medical device registration approval in Israel for its solution for near vision loss. With...
Presbia Coöperatief U.A. announced that it has received medical device registration approval in Israel for its solution for near vision loss. With this approval, the Flexivue Microlens(R), a safe, effective, reliable, and reversible treatment for presbyopia that eliminates dependence on reading glasses or contact lenses for seeing near objects, is now commercially available in more than 40 countri...
Presbia Coöperatief U.A. announced that it has received medical device registration approval in Israel for its solution for near vision loss. With this approval, the company said the Flexivue Microlens, a reversible treatment for presbyopia that eliminates dependence on reading glasses or contact lenses for seeing near objects, is now commercially available in more than 40 countries across Europe,...
Amsterdam, The Netherlands—Presbia has received medical device registration approval in Brazil and Israel for a 3-mm lens designed to be a reversible treatment for presbyopia (Flexivue Microlens). Brazil and Israel join a list of more than 40 countries across Europe, Latin America, and the Middle East where the implant is commercially available.
The company has signed an exclusive agreement with...
AMSTERDAM – (BUSINESS WIRE) – presbia, a medical device company and leader in the restoration of near vision, announced today it has received registration approval from the medical device in Israel for his solution to the loss of vision by. With this approval, the microlens Flexivue, a safe, efficient, reliable and reversible for presbyopia that eliminates the dependency on reading glasses or cont...